" class="no-js "lang="en-US"> Jennifer Ferrang - Medtech Alert
Sunday, October 12, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Jennifer Ferrang

Jennifer Ferrang

About Jennifer Ferrang

Business and Sales leader with combined experience from a Health Plan, Enterprise Software and Services Company and Quest Diagnostics. Proven ability to recruit,develop and drive a sales team to achieve results.

Specialties: Sales management, building and developing sales teams. Account Management and General Management.

Related Story

Appointments

 EmpiRx Health Announces Jennifer Ferrang as Chief Growth Officer | Pharmtech Focus

EmpiRx Health Announces Jennifer Ferrang as Chief Growth Officer

December 8 2021

EmpiRx Health, the industry’s only value-based pharmacy benefit manager (PBM), today announced it has appointed Jennifer […]